详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [2]Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China

出处：

DOI：

关键词： elderly multiple myeloma regulatory B cell stratification survival

摘要：

Despite the availability of new agents, elderly patients with multiple myeloma (MM) usually present with poor outcomes due to the heterogeneity of disease conditions, especially immune deficiency. Regulatory B cells (Bregs) can be involved in immune defects by exerting immune regulatory functions in MM. In order to provide more evidence-based practice for the elderly MM, the study established and assessed a stratified therapeutic model with studies on Bregs for Chinese Elderly Multiple Myeloma in 2021 (CEMM2021).In this open-label, non-interventional, prospective study in the real world, 159 newly diagnosed MM (NDMM) patients over 65 years old were sequentially recruited and bone marrow aspirates prior to treatment were obtained to detect the ratios of Bregs by flow cytometry.Based on the CEMM2021 model, 147 patients had received at least one cycle of induction therapy, including bortezomib/dexamethasone (Bd) (n = 80), lenalidomide/dexamethasone (Rd) (n = 27), Bd with a third agent X (Bd + X) (n = 27), and other regimens (n = 13). The proportions of patients achieving very good partial response or better were comparable among Bd, Bd + X, and Rd groups (41.9% vs. 54.5% vs. 44.0%, p = 0.472). Besides, the progression-free survival (PFS) and overall survival (OS) were not significantly different among Rd, Bd, and Bd + X groups. Multivariable analysis showed that induction efficacy less than partial response (PR) were poor prognostic factors for PFS, while Revised-International Staging System (R-ISS) III and efficacy less than PR were poor prognostic factors for OS. This study also found that the ratios of bone marrow Bregs <10% (p = 0.036) and SUVmax of PET-CT scan >4.2 (p = 0.000) were closely correlated with OS in the elderly MM.For the elderly NDMM, the CEMM2021 algorithm in our center might provide a valuable reference for the guidance of therapeutic strategies, with the combination of Bregs resulting in an effective and clinically meaningful prediction in contemporary treatment.© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

通讯作者：

通讯机构： [1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. [2]Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. [3]BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. [4]Pathogenesis and treatment of multiple myeloma. [5]High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma [6]Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. [7]RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor [8]多发性骨髓瘤疾病全周期健康管理 [9]Advances in research on potential inhibitors of multiple myeloma [10]Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of DLBCL patients